- Home
- HIG vs ALNY Comparison
HIG vs ALNY Comparison
Compare HIG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIG
- ALNY
- Stock Information
- Founded
- HIG 1810
- ALNY 2002
- Country
- HIG United States
- ALNY United States
- Employees
- HIG N/A
- ALNY N/A
- Industry
- HIG Property-Casualty Insurers
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- HIG Finance
- ALNY Health Care
- Exchange
- HIG Nasdaq
- ALNY Nasdaq
- Market Cap
- HIG 32.4B
- ALNY 35.0B
- IPO Year
- HIG 1995
- ALNY 2004
- Fundamental
- Price
- HIG $122.21
- ALNY $268.46
- Analyst Decision
- HIG Buy
- ALNY Strong Buy
- Analyst Count
- HIG 17
- ALNY 23
- Target Price
- HIG $123.65
- ALNY $319.27
- AVG Volume (30 Days)
- HIG 1.9M
- ALNY 872.0K
- Earning Date
- HIG 04-24-2025
- ALNY 05-01-2025
- Dividend Yield
- HIG 1.70%
- ALNY N/A
- EPS Growth
- HIG 29.86
- ALNY N/A
- EPS
- HIG 10.35
- ALNY N/A
- Revenue
- HIG $26,560,000,000.00
- ALNY $2,248,243,000.00
- Revenue This Year
- HIG $8.22
- ALNY $31.04
- Revenue Next Year
- HIG $5.31
- ALNY $23.56
- P/E Ratio
- HIG $11.82
- ALNY N/A
- Revenue Growth
- HIG 8.17
- ALNY 22.97
- 52 Week Low
- HIG $94.47
- ALNY $141.98
- 52 Week High
- HIG $124.90
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- HIG 64.68
- ALNY 55.64
- Support Level
- HIG $118.58
- ALNY $264.13
- Resistance Level
- HIG $123.70
- ALNY $300.90
- Average True Range (ATR)
- HIG 2.11
- ALNY 11.99
- MACD
- HIG 0.26
- ALNY 2.92
- Stochastic Oscillator
- HIG 80.67
- ALNY 53.73
About HIG Hartford Financial Services Group Inc. (The)
The Hartford Financial Services Group Inc offers a diverse range of property and casualty insurance, group benefits, and mutual fund services to a customer base of individuals and corporations. It operates in five segments: Commercial Lines, Personal Lines, Property & Casualty Other Operations, Group Benefits, and Hartford Funds, as well as a Corporate category.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.